Q32 Bio Inc.
NCM: QTTBLive Quote
📈 ZcoreAI Score
Our AI model analyzes Q32 Bio Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get QTTB Z-Score →About Q32 Bio Inc.
Healthcare
Biotechnology
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
📊 Fundamental Analysis
Q32 Bio Inc. demonstrates exceptional profitability, with a profit margin of 55.5%.
Return on Equity (ROE) is 125.1%, which reflects exceptional capital efficiency.
At a current price of $5.05, QTTB currently sits at the 55th percentile of its 52-week range (Range: $1.34 - $8.04).
💰 Valuation Insight
QTTB trades at a 91.7% discount (PE: 2.09), which may represent a value opportunity given the sector average of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
✅
Debt/Equity
Excellent
✅
Return on Equity
Excellent
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$73.88M
Trailing P/E
2.09
Forward P/E
-0.94
Beta (5Y)
-1.02
52W High
$8.04
52W Low
$1.34
Avg Volume
250K
Day High
Day Low